Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Have histologically confirmed invasive ER+, HER2- breast carcinoma
Be willing and able to provide pre- and on-treatment tumor samples
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale
Have adequate organ function
Be able to swallow capsules
Be a postmenopausal woman
You may not be if
Have bilateral invasive breast cancer
Have metastatic breast cancer
Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy
Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer
Have had prior radiotherapy to the ipsilateral chest wall for any malignancy
Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer
Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment
Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)
Have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled
Have another serious medical condition
Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years
